The Joint Base Lewis McChord Health Contracting Branch, is issuing this sources sought notice. The sources sought is being issued as a means of conducting market research to identify industrial capabilities that might exist in order to support an upcoming requirement for government for Molecular diagnostics Analyzer and Reagents for detection of the Antibodies and Pathogens: reagents and instrumentation for the qualitative, molecular detection of Herpes simplex virus (HSV 1 and 2), Congenital cytomegalovirus (CMV), Candida auris (C. auris), and Varicella Zoster Virus (VZV) organisms For additional information regarding the technical specifications, please refer to the attached DRAFT Statement of Work (SOW) and draft Salient Characteristics.
Based on the responses to this sources sought notice, this requirement may be set-aside for small business (in full or in part) or procured through full and open competition (unrestricted), the government intent at this time is for a single award. All small business set-aside categories will be considered. Telephonic inquiries will not be accepted or acknowledged, the government will not be providing evaluations or comments to companies providing sources sought responses, but the responses will be used to inform the government as to the best means of procuring this requirement.
This sources sought is for informational purposes only. This is not a “Request For Proposal (RFP)” to be submitted. It does not constitute a solicitation and shall not be construed as a commitment by the government. Responses in any form are not offers and the government is under no obligation to award a contract as a result of this announcement. No funds are available to pay for the preparation of responses to this announcement. Any information submitted by respondents to this technical description is strictly voluntary. Responses will not be returned to the responder. Not responding to this notice does not preclude participation in any future Request For Quote (RFQ) or Invitation For Bid (IFB) or Request For Proposals (RFP), if issued. If a solicitation is released it will be synopsized on the Government-Wide Point of Entry (GPE). It is the responsibility of potential offerors to monitor the GPE for additional information pertaining to this requirement.
Required Capabilities
The Contractor shall provide a platform or the diagnosis of infection with Herpes simplex virus (HSV), Congenital cytomegalovirus (CMV), Candida auris (C. auris), and Varicella Zoster Virus (VZV) organisms that are FDA approved for testing for individual all four analytes in the specified patient matrices outlined in the salient characteristics.
If your organization has the potential capacity and capabilities to perform these contract requirements, please provide the following information: Capabilities Statement, Organization Name, Point of Contact, CAGE code, and Unique Entity ID number.
Any applicable brochures or company capability material may also be submitted.
Eligibility
The applicable NAICS code for this requirement is 325413 - In-Vitro Diagnostic Substance Manufacturing. The size standard is 1250 employees. The product service code 6515 - Medical and Surgical Instruments, Equipment, and Supplies. Businesses of all sizes are encouraged to respond.
Submission Details
Interested parties are requested to submit via email. The email subject line should be “Sources Sought Response for W81K0224QA047.” The response to the sources sought may be in either Microsoft Word, Portable Document Format (PDF), or in the body of the email and shall be addressed to cindy.j.means.civ@health.mil.
All data received in response to this sources sought notice that is marked or designated as corporate or proprietary will be fully protected from release outside the government.
